PT  - JOURNAL ARTICLE
ED - American Society for Pharmacology and Experimental Therapeutics
TI  - ERRATUM
DP  - 1994 Dec 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 1720--1720
VI  - 271
IP  - 3
4099  - http://jpet.aspetjournals.org/content/271/3/1720.short
4100  - http://jpet.aspetjournals.org/content/271/3/1720.full
SO  - J Pharmacol Exp Ther1994 Dec 01; 271
AB  - S. L. Durham, C. M. Hare, M. R. Angelastro, J. P. Burkhart, J. R. Koehl, A. L. Marquart, S. Mehdi, N. P. Peet and M. J. Janusz: Pharmacology of N-[4-(4-morpholinylcarbonyl)benzoyl-l-valyl-N-[3,3,4,4,4-pentafluoro-1-(1-methylethyl)-2-oxobutyl]-l-prolinamide (MDL 101,146): A Potent Orally Active Inhibitor of Human Neutrophil Elastase. J. Pharmacol. Exp. Ther. 270(1): 185-191, 1994. Please note corrections to the article "Pharmacology of N-[4-(4-morpholinylcarbonyl)benzoyl-l-valyl-N-[3,3,4,4,4-pentafluoro-1-(1-methylethyl)-2-oxobutyl]-l-prolinamide (MDL 101,146): A Potent Orally Active Inhibitor of Human Neutrophil Elastase" by Durham et al., volume 270(1): 185-191. Specifically, page 186, Materials and Methods the right column, last line of the first paragraph should have read "substrate were used [S] = 0.05, 0.1, 0.4 or 1.0 mM; [I] = 0, 66.6, 133.3 or 200 nM." Also, page 187, the legend for figure 2 contains an error. MeoSuc-Ala-Ala-Pro-Val-(p-nitroanilide) concentrations were varied from 1.0 to 20 mM should be changed to 0.05 to 1 mM. The authors regret these errors.